FOI release

Freedom of Information request on the fatalities relating to COVID-19 vaccinations (FOI 21/910)

Published 20 January 2022

3rd September 2021

FOI 21/910

Dear

Thank you for your email dated 5th August 2021, where you asked: “Please could you inform me how many, if any, fatalities there have been following those vaccinations?”

We can confirm that we do not hold this information as we do not collect complete fatality data. We suggest you contact the Office for National Statistics for death statistics, please find below contact details;

Email: info@ons.gov.uk
Reports received through our Yellow Card scheme include some fatality reports and these can be viewed by following the link below: https://www.gov.uk/government/publications/coronavirus-covid-19-vaccine-adverse-reactions

The MHRA intends to publish all suspected reactions reported in association with available COVID-19 vaccines in an interactive format as interactive Drug Analysis Profiles (iDAPs), along with our ADR summary that is published each week. The use of iDAPs will enable users to view the data by categories of their choice such as age, sex and seriousness of reports. Users will also be able to download the data tables in CSV format.

As we plan to publish the data, we consider that your request is covered by Section 22 of the Freedom of Information Act (information intended for future publication) and the information you have asked for is therefore exempt from disclosure.

Section 22 is a qualified exemption which means we have considered whether there is a greater public interest in releasing the information requested or withholding it. We recognise there is strong interest in seeing this data and accept it should not be withheld however wish to publish this information alongside appropriate context and assessment.

I hope the information provided is helpful, but if you are dissatisfied with the handling of your request, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date of this response; and can be addressed to this email address.

Yours sincerely,

FOI Team

Vigilance and Risk Management of Medicines Division